LUMO is expected to report earnings to fall 27.62% to -66 cents per share on March 06
Q4'24
Est.
$-0.67
Q3'24
Missed
by $0.18
Q2'24
Beat
by $0.24
Q1'24
Missed
by $0.30
Q4'23
Missed
by $3.04
The last earnings report on November 12 showed earnings per share of -92 cents, missing the estimate of -73 cents. With 481.69K shares outstanding, the current market capitalization sits at 37.53M.
a clinical-stage biopharmaceutical company, which engages in the development of therapeutics for the treatment of Pediatric Growth Hormone Deficiency (PGHD)